Clinical Takeaway
Plant-derived cannabidiol (CBD) oral solution produced meaningful reductions in drop seizures in patients with Lennox-Gastaut syndrome even at thresholds below the standard 50% benchmark used in clinical trials. Caregiver-reported outcomes confirmed that smaller seizure reductions were still associated with real-world improvements in patient condition, supporting the use of caregiver global impression scales as valid measures of clinical benefit. These findings suggest that rigid percentage-based endpoints may underestimate the true therapeutic value of CBD in this severe pediatric epilepsy population.
#22 Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.
Citation: Specchio Nicola et al.. Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox-Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials.. CNS drugs. 2025. PMID: 40775196.
Design: 5 Journal: 0 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
Lennox-Gastaut syndrome represents a severe, treatment-resistant epilepsy where drop seizures cause significant morbidity and mortality, making identification of meaningful clinical endpoints critical for treatment evaluation. This post hoc analysis demonstrates that cannabidiol produces clinically meaningful reductions in drop seizures at thresholds lower than the conventional 50% reduction benchmark, potentially identifying a more granular measure of therapeutic benefit that correlates with caregiver-perceived improvement. For practitioners managing LGS patients, these findings provide evidence-based guidance on realistic treatment response expectations and may inform individualized benefit-risk discussions with families regarding cannabis-based therapeutics.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND AND OBJECTIVE: In clinical trials of patients with Lennox-Gastaut syndrome (LGS), a ≥ 50% reduction in drop seizure frequency is generally accepted as a key endpoint. However, smaller reductions (< 50%) may yet be impactful for patients in real-world settings. This exploratory analysis evaluated the threshold for a clinically important response in drop seizures that is associated with the Caregiver Global Impression of Change (CGIC) scale score in patients with LGS treated with cannabidiol (CBD) oral solution and assessed the suitability of CGIC as an anchor for meaningful change. METHODS: This exploratory post hoc analysis included patients with LGS (N = 215, age 2-55 years) receiving CBD (Epidiolex® [USA]/Epidyolex® [EU]; 100 mg/mL oral solution) in two phase 3 randomized placebo-controlled trials (NCT02224690, April-October 2015, and NCT02224560, June- December 2015). Reduction in drop seizures (involving sudden loss of muscle tone) was anchored to CGIC scores of "slightly improved" or better or "much improved" or better, to determine the threshold at which seizure reduction can be considered clinically meaningful to patients. Spearman's correlation indicated suitability of anchors (absolute value ≥ 0.30 deemed appropriate). RESULTS: In the 215 patients receiving CBD with a CGIC score recorded, CGIC was "slightly improved" or better in 60% of patients, and "much improved" or better in 31% after 14 weeks of treatment. With a CGIC rating of "slightly improved" or better, the best threshold for a clinically important response in drop seizure reduction was – 30.6% (57.7% of patients). Mean and median percentage reductions in drop seizures were – 46.9% and – 58.6%, respectively. Using "much improved" or better, the best threshold was – 49.6% (40.5% of patients). Mean and median percentage reductions in drop seizures were – 57.6% and – 66.0%, respectively. Spearman's correlation was 0.47. CONCLUSION: Anchoring to CGIC of "slightly improved" or better, the th
🧠 This post hoc analysis of cannabidiol trials in Lennox-Gastaut syndrome usefully challenges the convention that only seizure reductions exceeding 50% matter clinically, demonstrating that caregivers perceive meaningful improvement at lower thresholds of drop seizure reduction. While the CGIC scale provides valuable real-world perspective, it’s important to recognize that post hoc analyses carry inherent limitations around multiple comparisons, retrospective outcome selection, and potential bias toward favorable results, and that caregiver perception, though clinically relevant, may not fully capture patient-centered outcomes like quality of life, mood, or cognitive function. The heterogeneity of LGS populations and individual variation in seizure burden baseline also mean that any threshold derived here requires validation in prospective studies before widespread application. For practitioners, this work provides preliminary evidence that meaningful clinical benefit in drop seizures may manifest below the traditional 50% reduction benchmark, potentially allowing for more nuanced shared decision-making with families about whether the seizure reduction